Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 2;9:669132. doi: 10.3389/fcell.2021.669132

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Zhang, Li, Zhong, Zhang, Sun and Zhu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

MCM5/HDAC1 complex led to poor prognosis in lung cancer patients. Sixty-one clinical lung cancer tissues were collected and used to analyze MCM5, HDAC1, and E-cadherin expression, as well as their effect on survival rate. (A) Immunohistochemistry was performed to detect MCM5 and HDAC1 expression in lung cancer tissues at different clinical stages. (B) MCM5 expression in lung cancer patients. (C) HDAC1 expression in lung cancer patients. (D) E-cadherin expression in lung cancer tissues at different clinical stages. (E) E-cadherin expression in metastatic and non-metastatic lung cancer. (F) Kaplan–Meier plots of the overall survival rate of patients with lung cancer having low (blue) or high (red) MCM5/HDAC1 levels. *P < 0.05.